ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

59.60
-0.97
(-1.60%)
At close: June 20 4:00PM
59.0849
-0.5151
( -0.86% )
After Hours: 7:09PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
59.0849
Bid
59.16
Ask
60.00
Volume
1,262,518
58.05 Day's Range 60.19
0.00 52 Week Range 0.00
Market Cap
Previous Close
60.57
Open
60.05
Last Trade
1
@
60.24
Last Trade Time
19:19:26
Financial Volume
$ 74,767,013
VWAP
59.2206
Average Volume (3m)
-
Shares Outstanding
80,275,950
Dividend Yield
-
PE Ratio
-33.76
Earnings Per Share (EPS)
-1.91
Revenue
371.21M
Net Profit
-153.61M

About CRISPR Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Zug, Che
Founded
1970
CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRSP. The last closing price for CRISPR Therapeutics was $60.57. Over the last year, CRISPR Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

CRISPR Therapeutics currently has 80,275,950 shares outstanding. The market capitalization of CRISPR Therapeutics is $5.19 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -33.76.

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow

Bearish

Net Premium

-2M

Calls / Puts

37.50%

Buys / Sells

83.33%

OTM / ITM

22.22%

Sweeps Ratio

0.00%

CRSP Latest News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPECSpectaire Holdings Inc
$ 0.8308
(144.35%)
8.13M
SRPTSarepta Therapeutics Inc New
$ 167.00
(35.22%)
850.24k
BRNSBarinthus Biotherapeutics PLC
$ 1.51
(20.80%)
3.26k
KTRAKintara Therapeutics Inc
$ 0.3236
(17.72%)
12.05M
LGHLWLion Group Holding Ltd
$ 0.0075
(15.38%)
21.05k
RELIReliance Global Group Inc
$ 0.511
(-15.38%)
1.92M
PBMPsyence Biomedical Ltd
$ 0.52
(-13.33%)
8.85M
SMXSMX Security Matters Public Company
$ 0.1447
(-10.01%)
2.18M
LDTCLeddarTech Holdings Inc
$ 0.874
(-8.58%)
500
VMARVision Marine Technologies Inc
$ 0.58
(-8.08%)
88.02k
ZCARZoomcar Holdings Inc
$ 0.1645
(12.52%)
13.7M
KTRAKintara Therapeutics Inc
$ 0.3236
(17.72%)
12.05M
NVDANVIDIA Corporation
$ 130.42
(-0.28%)
11.84M
PBMPsyence Biomedical Ltd
$ 0.527
(-12.17%)
8.85M
SPECSpectaire Holdings Inc
$ 0.8308
(144.35%)
8.13M

CRSP Discussion

View Posts
axelvento axelvento 3 weeks ago
I agree.....solid company$$$$$$$$
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 weeks ago
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isnโ€™t going to zero
👍️ 1
axelvento axelvento 1 month ago
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 month ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 month ago
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 month ago
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 months ago
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
๐Ÿ‘๏ธ0
OldAIMGuy OldAIMGuy 2 months ago
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
๐Ÿ‘๏ธ0
OldAIMGuy OldAIMGuy 2 months ago
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
CRSP over $30
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
CRSP new 52 week high
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 4 months ago
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 4 months ago
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 4 months ago
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 4 months ago
Didnโ€™t tank like BLUE
Recovered


More analysis from Nanolyze

๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1 🤡 1
jondoeuk jondoeuk 5 months ago
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 5 months ago
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 5 months ago
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 6 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY
👍️ 1
OldAIMGuy OldAIMGuy 6 months ago
Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
Windbag1014,

Thanks for your views and informative response. GLTY & GLTA
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
OldAIMGuy,

Thanks for your clear and detailed response.

Your approach and strategy dealing with what Crispr T AG stock price movement over time shows, and the Crispr company activity makes good sense. More power and good luck to you.

John
👍️ 1
OldAIMGuy OldAIMGuy 6 months ago
Hi JJ8, Re: CRSP price action..........................

My guess is it's a "Sell on the News" action. This isn't the first time CRSP has shown high amplitude price change as this histogram shows:
https://schrts.co/NSfSbXYF

I think it will be important to watch the transition of this company from basically a 'research' business to one of product development and distribution. Somewhere along the way they'll have to show a profit to reward those who've invested in them. I'm fond of watching the Accumulation/Distribution activity to see what is happening with strong and weak hands holding the stock. In the mean time I plan on trimming and backfilling my position as the price moves around. I last added 12% to my position at $47.56 in August and had the opportunity to part with 10% of the holding at $69.57 a few weeks ago. The core position remains.



With each cycle of the price the portfolio builds out a bit.

Hope this helps,
OAG
๐Ÿ‘๏ธ0
Windbag1014 Windbag1014 6 months ago
Vertex set the price of Casgevy at $2.2 million compared to $3.1 million for Bluebirdโ€™s Lyfgenia. Bluebirdโ€™s gene therapy for thalassemia, approved last year, has a list price of $2.8 million.

The therapies are also not easy to receive. Patients must spend weeks, even months, in the hospital before and after the therapy is administered. And some of the preparatory steps can cause serious side effects, including severe infections, nausea, painful mouth sores, and infertility.

https://www.statnews.com/2023/12/08/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease/#:~:text=Vertex%20set%20the%20price%20of%20Casgevy%20at%20%242.2,year%2C%20has%20a%20list%20price%20of%20%242.8%20million.

Prohibitive treatment
👍️ 1
YankeMike YankeMike 6 months ago
Probably just because the share price had run up so much before the approval, so it was kind of baked-in already and some took profits. Also, maybe because of high price tag of the treatment. Still a bright future and should trend upwards.
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
The dump of Crisp shares last Friday Dec 8th after the "good" news is confusing.

The institutional ownership is 63.48%. Why this response by share owners. I assume it probably was mainly by the institutions. But why at this time? Profit taking? Haven't done a check on insiders transactions yet.

More than 17 million shares traded in one session. The average daily volume of trading happens to be about 2-3 millions of shares daily. Why the exodus a this time of "good" news.

My profits were cut in half in one session. I don't intend to sell at such times.
Actually, I buy usually. That's what I did recently after the sudden drop in Walmart share price.

Any ideas and thoughts? What's going on behind the scene? TIA

GLTA
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
Emmanuelle Charpentier, age 54, founder of Crispr Therapeutics AG
👍️ 1
TheFinalCD TheFinalCD 6 months ago
Casgevy, developed by partners Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), and bluebird bio's (BLUE.) Lyfgenia were approved for people aged 12 years and older.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
CRSP share price sharp reversal by Double Bottom Breakdown today on 8-Dec-2023. This type of rapid reversals based on company news developments. C'est La Vie in stock trading. GLTA
๐Ÿ‘๏ธ0
BuckeyeStocks BuckeyeStocks 6 months ago
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
👍️ 2
Monksdream Monksdream 6 months ago
What are the bleep are you talking about without pasting a chart to back up your assertion
๐Ÿ‘๏ธ0
JJ8 JJ8 6 months ago
CRSP share price Spread Triple Top Breakout today on 06-Dec-2023. GLTA
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 7 months ago
Smart move. Don't waste resources, learn from the clinical data and improve the pipeline https://finance.yahoo.com/news/crispr-therapeutics-announces-updates-immuno-211500451.html
👍️ 1
rayank rayank 7 months ago
Is the 12/8 FDA approval in the price already?
๐Ÿ‘๏ธ0
JJ8 JJ8 7 months ago
CRSP share price Low Pole Reversal today on 04-Dec-2023. We had 3 sessions of trading in Dailies that was in Downtrend while the Weeklies are in Uptrend. It seems the Weeklies more likely to continue should this week the trend in Dailies continue to keep support of the Weekly Uptrend. We shall see. GLTA
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
UR welcome
I came across CRSP three years ago and learned about the discoverers of the technology, Jennifer Doudna and Emmanuelle Charpentier who shared the 2020 Nobel for chemistry
I have been following the technology since, including Jennifer Doudnaโ€™s Nobel lecture
Clustered
Regularly
Interspersed
Short
Palindromic
Repeats
๐Ÿ‘๏ธ0
JJ8 JJ8 7 months ago
Interesting and informative analysis. Thanks for posting. GLTY & GLTA
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
Older YouTube interview with Sam Kulkarni CRSP CEO
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
Good capsule analysis by a YouTuber
Not all of them are shills
👍️ 1
JJ8 JJ8 7 months ago
CRSP share price Double Bottom Breakdown today on 30-Nov-2023. The Daily turned Downtrend in this trading session while the Weeklies are still in Uptrend as of this week. We shall see what path it may choose to follow. I am optimistic for the long term at this time.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 7 months ago
We should get data from the VCTX210 and VCTX211 trials next year https://news.ubc.ca/2023/11/27/stem-cell-based-treatment-for-type-1-diabetes/
👍️ 1
rayank rayank 7 months ago
9:10 am ET November 29, 2023 (Benzinga) Print
On CNBCโ€™s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. I think itโ€™s got to come down a little because the stock is losing a lot of money."
๐Ÿ‘๏ธ0
rayank rayank 7 months ago
Ok so maybe the FDA approval on Dec. 8th is already built into the price of CRSP during it's recent surge? That is kind of what I am thinking that if they do get the approval, that maybe it doesn't go up much more if any at all? But VRTX going down on the UK day of approval seems to me a puzzle?
๐Ÿ‘๏ธ0